ACC

Refer to important disclosures at the end of this report

Cost savings initiatives yielding results

CMP: Rs 1,563 as of (October 19, 2020 TP: Rs 1,774 (■)

Rating: BUY (■)

Upside: 13.5 %



•	ACC's Q3 results were above our estimates, led by higher-than-estimated realization (up
	3.5% yoy vs. estimate of 1.4% growth). EBITDA stood at Rs6.7bn vs. estimated Rs6.3bn
	and EBITDA/ton came in at Rs1.073 vs. estimated Rs958.

- Key positives: 1) 10.2% yoy decline in freight costs, despite increase in diesel prices, due to higher inter-company purchases and increase in direct dispatches, in our view; 2) 20% yoy decline in other expense; 3) realization decline restricted at mere 1.1% qoq. Key negative was a 43% yoy decline in RMC volume, leading to a 44.3% yoy fall in revenue.
- Cement EBITDA/ton stood at Rs1,073 vs. Rs851/Rs1,173 in Q3CY19/Q2CY20. Grinding capacity expansion of 1.1mt in Sindri, Jharkhand, is expected by Mar'21, while capacity expansion of 4.8mt in the Central region is expected by CY22-end.
- ACC started a cost reduction initiative "Project Parvat" in CY19 with an aim to reduce operating costs by Rs200/ton till CY21. Valuations are attractive at 8.8x/8.1x CY21/CY22E EV/EBITDA and an EV/ton of US\$95. We maintain Buy and OW in sector EAP.

Lower opex and higher realization help profits: ACC benefitted from high cement prices and low opex in Q3. Realization was down by mere 1.1% qoq (but up 3.5% yoy) led by an increase in sales of premium products (up 5pp qoq) and lower sales in the East region, where the price decline was sharper. Sales volume was up 0.8% yoy with capacity utilization of 77%. RMC sales volume was down 43% yoy. Variable costs fell Rs35/ton yoy (flat qoq) on lower energy costs and operating efficiencies. Employee cost was down 11.1% yoy/13.9% qoq due to the reduction in contractual employees. Freight expense was down 10.2% yoy led by higher direct dispatches. Other expense/ton fell 20% yoy, driven by cost-saving initiatives (rent, ad spends, office and travel expense etc.). Purchase of stock-in-trade was up 2.6x yoy, which we believe is due to higher inter-company purchases. Lower opex and higher realization led to 20.6% yoy growth in EBITDA and 3.2pp yoy improvement in OPM. Cement EBITDA/ton was up 26.1% yoy. Profit increased 21% yoy.

Cost savings in progress; maintain Buy on attractive valuations: Improvement in cement demand after the easing of lockdowns surprised us positively and we recently upgraded earnings estimates for the entire sector (Report Link). ACC is working on cost saving strategies and started an initiative "Project Parvat" in CY19 with an aim to reduce fixed costs by Rs200/ton in CY20-21. The savings were to be achieved through improving efficiencies in procurement and supply chain and lowering distribution costs. Higher inter-company purchases in 9MCY20 (up 1.9x yoy) indicates progress in achieving benefits of the Master Supply Agreement signed between ACC and Ambuja. Capacity expansion plans of 5.9mt (1.1mt by Mar'21 and 4.8mt by CY22-end) will help volume growth in future. We believe that valuations are attractive at 8.8x/8.1x CY21E EV/EBITDA and US\$95 EV/ton. ACC has traded at an average EV/EBITDA of 11.6x and EV/ton of US\$122 between CY07 and CY20. We maintain Buy with a TP of Rs1,774 (9.5x CY22E EV/EBITDA). We are OW on ACC in our sector EAP. Key downside risks include lower-than-estimated cement demand growth, which in turn, may impact prices.

Please see our sector model portfolio (Emkay Alpha Portfolio): Cement & Building Materials (page 8)

Financial Snapshot (Standalone)

(Rs mn)	CY18	CY19	CY20E	CY21E	CY22E
Net Sales	1,48,014	1,56,567	1,39,186	1,56,253	1,65,374
EBITDA	21,150	24,095	23,918	26,828	29,083
EBITDA Margin (%)	14.3	15.4	17.2	17.2	17.6
APAT	10,764	13,589	13,039	14,957	16,416
EPS (Rs)	57.3	72.3	69.4	79.6	87.3
EPS (% chg)	17.6	26.2	(4.0)	14.7	9.8
ROE (%)	10.8	12.3	10.9	11.4	11.5
P/E (x)	27.3	21.6	22.5	19.6	17.9
EV/EBITDA (x)	12.4	10.3	10.0	8.8	8.1
P/BV (x)	2.8	2.5	2.3	2.2	2.0

Source: Company, Emkay Research

Change in Estimates	
EPS Chg CY20E/CY21E (%)	-/-
Target Price change (%)	NA
Target Period (Months)	12
Previous Reco	BUY

Emkay vs Consensus

EPS Estimates
CY20E

CY21E

Emkay	69.4	79.6
Consensus	63.1	74.8
Mean Consensus TP (12N	1) Rs	s 1,597
Stock Details		
Bloomberg Code		ACC IN
Face Value (Rs)		10
Shares outstanding (mn)		188
52 Week H/L	1,59	91 / 895
M Cap (Rs bn/USD bn)	293	3 / 4.00
Daily Avg Volume (nos.)	11	,12,583
Daily Avg Turnover (US\$ r	nn)	21.3


Shareholding Pattern Sep '20

Promoters	54.5%
FIIs	6.7%
DIIs	25.5%
Public and Others	13.3%

Price Performance

(%)	1M	3M	6M	12M
Absolute	9	19	33	1
Rel. to Nifty	6	9	4	(1)

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:


Sanjeev Kumar Singh

sanjeev. singh@emkayglobal.com

+91 22 6612 1255


Story in Charts

Exhibit 1: Sales volumes up 0.8% yoy, recovery seen qoq




Source: Company, Emkay Research

Exhibit 3: Variable cost/ton down Rs35/ton yoy




Source: Company, Emkay Research

Exhibit 5: OPM improves 3.2pp yoy, down 1.2pp qoq




Source: Company, Emkay Research

Exhibit 2: Realization up 3.4% yoy but down 1.1% qoq




Source: Company, Emkay Research

Exhibit 4: Freight costs/ton down 10.2% yoy, but up 5.9% qoq



Source: Company, Emkay Research

Exhibit 6: Cement EBITDA/ton up 26.1% yoy, but down 8.5% qoq



Source: Company, Emkay Research

Exhibit 7: Actual vs. estimates (Q3CY20)

Particulars/Rs mn	Actual	Estir	nates	% vai	riation	Comment
raiticulais/NS IIIII	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Sales	35,373	35,354	34,308	0.1	3.1	In-line with results
EBITDA	6,707	6,292	5,842	6.6	14.8	Led by lower freight costs
EBITDA margin (%)	19	17.8	17	116	193	
Adj. PAT	3,631	3,378	3,098	7.5	17.2	Led by higher operating profits

Source: Company, Emkay Research, Bloomberg

Exhibit 8: Quarterly Results

Exhibit 8: Quarterly Resi	Q3CY19	Q4CY19	Q1CY20	Q2CY20	Q3CY20	YoY (%)	QoQ (%)	9MCY20	9MCY19	YoY (%)
Revenue	35,276	40,603	35,017	26,008	35,373	0.3	36.0	96,399	115,964	(16.9)
Expenditure	29,713	35,197	29,159	20,764	28,666	(3.5)	38.1	78,589	97,275	(19.2)
as % of sales	84.2	86.7	83.3	79.8	81.0	(0.0)	0011	81.5	83.9	(10.2)
Consumption of RM	5,225	5,231	5,300	2,179	3,840	(26.5)	76.3	11,318	17,350	(34.8)
as % of sales	14.8	12.9	15.1	8.4	10.9	(20.0)	, 0.0	11.7	15.0	(0)
Inv. adjustments	(2,120)	3,246	(1,647)	1,254	668	n/m	(46.8)	275	(2,238)	n/m
as % of sales	(6.0)	8.0	(4.7)	4.8	1.9	.,	(1010)	0.3	(1.9)	
Employee Cost	2,290	2,325	2,085	1,762	2,052	(10.4)	16.4	5,898	6,315	(6.6)
as % of sales	6.5	5.7	6.0	6.8	5.8	(-)	-	6.1	5.4	()
Power & Fuel	7,840	7,400	7,338	4,570	6,295	(19.7)	37.7	18,204	23,913	(23.9)
as % of sales	22.2	18.2	21.0	17.6	17.8	,		18.9	20.6	, ,
Purchase of stocks	879	1,038	1,102	1,561	2,293	160.8	46.9	4,956	2,579	92.2
as % of sales	2.5	2.6	3.1	6.0	6.5			5.1	2.2	
Freight	9,548	9,895	9,457	6,034	8,638	(9.5)	43.2	24,129	30,606	(21.2)
as % of sales	27.1	24.4	27.0	23.2	24.4			25.0	26.4	
Other expenditure	6,050	6,063	5,524	3,404	4,881	(19.3)	43.4	13,809	18,749	(26.4)
as % of sales	17.2	14.9	15.8	13.1	13.8			14.3	16.2	
EBITDA	5,563	5,406	5,859	5,244	6,707	20.6	27.9	17,810	18,689	(4.7)
Depreciation	1,504	1,600	1,571	1,618	1,600	6.4	(1.1)	4,788	4,430	8.1
EBIT	4,060	3,806	4,288	3,626	5,108	25.8	40.8	13,022	14,259	(8.7)
Other Income	508	560	547	502	449	(11.6)	(10.6)	1,498	1,557	(3.8)
Interest	163	292	106	131	160	(1.5)	22.4	397	570	(30.4)
PBT	4,405	4,074	4,728	3,998	5,397	22.5	35.0	14,123	15,246	(7.4)
Total Tax	1,406	1,381	1,529	1,318	1,766	25.6	34.0	4,613	5,344	(13.7)
Adjusted PAT	3,000	2,692	3,199	2,680	3,631	21.0	35.5	9,510	9,902	(4.0)
PAT after MI	3,000	2,692	3,199	2,680	3,631	21.0	35.5	9,510	9,902	(4.0)
Extra ordinary items	-	-	-	-	-			-	995	n/m
Reported PAT	3,000	2,692	3,199	2,680	3,631	21.0	35.5	9,510	10,897	(12.7)
Adjusted EPS (Rs)	16.0	14.3	17.0	14.3	19.3	21.0	35.5	50.6	52.7	(4.0)
Margine (0/)						(hma)	(hma)			(hna)
Margins (%)	45.0	40.0	40.7	00.0	40.0	(bps)	(bps)	40.5	10.1	(bps)
EBIDTA	15.8	13.3	16.7	20.2	19.0	319	(120)	18.5	16.1	236
EBIT	11.5	9.4	12.2	13.9	14.4	293	50	13.5	12.3	121
EBT	12.5	10.0	13.5	15.4	15.3	277	(12)	14.7	13.1	150
PAT	8.5	6.6	9.1	10.3	10.3	176	(4)	9.9	8.5	133
Effective Tax rate	31.9	33.9	32.3	33.0	32.7	82	(25)	32.7	35.1	(239)

Source: Company, Emkay Research

Exhibit 9: Operating cost analysis on per ton basis

Rs/ton	Q3CY19	Q4CY19	Q1CY20	Q2CY20	Q3CY20	YoY (%)	QoQ (%)	9MCY20	9MCY19	YoY (%)
Sales volumes (mt)	6.4	7.8	6.6	4.8	6.5	0.8	35.2	17.9	21.1	(15.4)
Raw Material	811	674	808	454	592	(27.1)	30.4	634	822	(22.9)
Inv. adjustments	(329)	418	(251)	261	103	n/m	(60.6)	15	(106)	n/m
Staff cost	356	300	318	367	316	(11.1)	(13.9)	330	299	10.4
Power & Fuel	1,217	954	1,119	952	970	(20.3)	1.9	1,020	1,133	(10.0)
Purchase of stocks	137	134	168	325	353	158.8	8.7	278	122	127.2
Freight	1,483	1,275	1,442	1,257	1,331	(10.2)	5.9	1,352	1,451	(6.8)
Other expenses	939	781	842	709	752	(20.0)	6.1	774	889	(12.9)
Operating cost	4,614	4,536	4,445	4,326	4,417	(4.3)	2.1	4,403	4,610	(4.5)
EBITDA/ton*	851	606	833	1,173	1,073	26.1	(8.5)	998	886	12.6
Realization	4,922	4,658	4,702	5,144	5,090	3.4	(1.1)	5,084	5,053	0.6

Source: Company, Emkay Research, * adjusted for RMC segment's profits

Exhibit 10: Key Assumptions

-xp						
	CY17	CY18	CY19	CY20E	CY21E	CY22E
Cement Sales (mt)	26.2	28.4	28.9	25.7	28.7	29.6
Realization (Rs/ton)	4,419	4,597	4,709	4,837	4,811	4,912
Per ton costs (Rs)						
Raw material	769	835	782	787	794	800
Employee cost	312	286	299	309	296	304
Power & Fuel	1036	1057	1084	1062	1080	1104
Freight	1317	1414	1402	1406	1391	1410
Other expenses	911	892	859	809	833	864
Total Cost	4,340	4,472	4,585	4,487	4,510	4,611


Source: Company, Emkay Research

Exhibit 11: Peer valuation

Company	Rs bn	EV/EBITDA (x)			EV	EV/Ton (US\$)			EPS (Rs)			P/E (x)		
Company	Мсар	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
ACC*	293	10.0	8.8	8.1	97	95	94	69.4	79.6	87.3	22.5	19.6	17.9	
Ambuja Cements*	492	13.9	12.6	10.5	158	145	138	8.7	9.1	10.5	28.3	27.2	23.5	
India Cements	37	9.5	8.7	7.5	59	57	54	4.9	5.7	7.6	24.5	20.8	15.7	
Ramco Cements	185	17.4	16.7	14.1	144	135	130	22.8	22.6	28.6	34.4	34.6	27.4	
Shree Cements	761	20.9	17.8	15.5	225	210	204	450.4	530.3	604.3	46.8	39.8	34.9	
UltraTech Cement	1,303	14.6	12.9	11.0	164	157	149	156.8	186.4	220.8	28.8	24.2	20.5	
JK Lakshmi Cement	33	6.2	5.4	4.6	44	42	38	20.0	23.7	27.8	14.0	11.8	10.1	
JK Cement	139	13.3	12.2	10.9	130	128	126	57.2	67.2	79.8	31.4	26.7	22.5	
Orient Cement	12	5.1	4.9	4.4	37	35	32	6.5	6.3	7.2	9.0	9.3	8.1	
Prism Cement	35	14.4	10.3	8.7	98	98	95	-0.4	1.4	2.5	-175.5	47.9	27.6	
Star Cement	34	8.3	6.3	5.5	76	70	66	6.1	7.5	7.9	13.4	11.0	10.3	
Birla Corp	49	6.9	6.5	5.6	71	59	54	50.9	58.0	67.7	12.4	10.9	9.3	


Source: Company, Emkay Research, * December ending companies

Exhibit 12: ACC's 1-yr forward EV/ton chart



Source: Company, Bloomberg, Emkay Research

Exhibit 13: ACC's 1-yr forward EV/EBITDA chart



Source: Company, Bloomberg, Emkay Research

Key Financials (Standalone)

Income Statement

Y/E Dec (Rs mn)	CY18	CY19	CY20E	CY21E	CY22E
Net Sales	1,48,014	1,56,567	1,39,186	1,56,253	1,65,374
Expenditure	1,26,864	1,32,472	1,15,268	1,29,424	1,36,291
EBITDA	21,150	24,095	23,918	26,828	29,083
Depreciation	5,996	6,030	6,344	6,453	6,584
EBIT	15,154	18,065	17,574	20,375	22,499
Other Income	1,385	3,112	2,339	2,467	2,603
Interest expenses	892	862	420	483	561
PBT	15,647	20,315	19,493	22,360	24,541
Tax	4,883	6,726	6,453	7,403	8,125
Extraordinary Items	4,303	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	15,066	13,589	13,039	14,957	16,416
Adjusted PAT	10,764	13,589	13,039	14,957	16,416

Balance Sheet

Y/E Dec (Rs mn)	CY18	CY19	CY20E	CY21E	CY22E
Equity share capital	1,880	1,880	1,880	1,880	1,880
Reserves & surplus	1,03,397	1,13,333	1,23,233	1,34,528	1,46,758
Net worth	1,05,277	1,15,213	1,25,113	1,36,408	1,48,638
Minority Interest	0	0	0	0	0
Loan Funds	0	0	0	0	0
Net deferred tax liability	6,631	6,422	6,422	6,422	6,422
Total Liabilities	1,11,908	1,21,635	1,31,535	1,42,830	1,55,060
Net block	70,610	70,018	68,028	69,575	65,991
Investment	2,302	2,302	2,302	2,302	2,302
Current Assets	83,418	94,148	1,06,108	1,11,186	1,14,434
Cash & bank balance	28,368	43,832	52,013	55,731	57,205
Other Current Assets	11,079	12,288	12,288	12,288	12,288
Current liabilities & Provision	48,343	49,186	52,903	52,232	52,666
Net current assets	35,075	44,962	53,206	58,954	61,768
Misc. exp	0	0	0	0	0
Total Assets	1,11,908	1,21,635	1,31,535	1,42,830	1,55,060

Cash Flow

Y/E Dec (Rs mn)	CY18	CY19	CY20E	CY21E	CY22E
PBT (Ex-Other income) (NI+Dep)	14,943	20,315	17,154	19,893	21,938
Other Non-Cash items	(472)	(254)	0	0	0
Chg in working cap	(3,881)	2,661	(63)	(2,029)	(1,341)
Operating Cashflow	11,181	22,484	17,401	17,396	19,617
Capital expenditure	(4,951)	(4,935)	(8,000)	(12,000)	(16,000)
Free Cash Flow	6,230	17,549	9,401	5,396	3,617
Investments	(1,177)	43	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(3,678)	(3,283)	(5,661)	(9,533)	(13,397)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(606)	0	0	0	0
Dividend paid (incl tax)	(3,396)	(3,169)	(3,139)	(3,662)	(4,186)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(4,411)	(3,742)	(3,559)	(4,145)	(4,747)
Net chg in cash	3,092	15,459	8,181	3,719	1,473
Opening cash position	25,268	28,368	43,832	52,013	55,731
Closing cash position	28,368	43,832	52,013	55,731	57,205

Source: Company, Emkay Research

Key Ratios

Profitability (%)	CY18	CY19	CY20E	CY21E	CY22E
EBITDA Margin	14.3	15.4	17.2	17.2	17.6
EBIT Margin	10.2	11.5	12.6	13.0	13.6
Effective Tax Rate	31.2	33.1	33.1	33.1	33.1
Net Margin	7.3	8.7	9.4	9.6	9.9
ROCE	15.6	18.1	15.7	16.7	16.9
ROE	10.8	12.3	10.9	11.4	11.5
RoIC	20.6	24.3	25.0	28.7	31.4

Per Share Data (Rs)	CY18	CY19	CY20E	CY21E	CY22E
EPS	57.3	72.3	69.4	79.6	87.3
CEPS	89.2	104.4	103.1	113.9	122.3
BVPS	560.0	612.9	665.5	725.6	790.7
DPS	14.0	14.0	12.0	14.0	16.0

Valuations (x)	CY18	CY19	CY20E	CY21E	CY22E
PER	27.3	21.6	22.5	19.6	17.9
P/CEPS	17.5	15.0	15.2	13.7	12.8
P/BV	2.8	2.5	2.3	2.2	2.0
EV / Sales	1.8	1.6	1.7	1.5	1.4
EV / EBITDA	12.4	10.3	10.0	8.8	8.1
Dividend Yield (%)	0.9	0.9	0.8	0.9	1.0

Gearing Ratio (x)	CY18	CY19	CY20E	CY21E	CY22E
Net Debt/ Equity	(0.3)	(0.4)	(0.4)	(0.4)	(0.4)
Net Debt/EBIDTA	(1.5)	(1.9)	(2.3)	(2.2)	(2.0)
Working Cap Cycle (days)	16.5	2.6	3.1	7.5	10.1

Growth (%)	CY18	CY19	CY20E	CY21E	CY22E
Revenue	11.4	5.8	(11.1)	12.3	5.8
EBITDA	10.8	13.9	(0.7)	12.2	8.4
EBIT	19.4	19.2	(2.7)	15.9	10.4
PAT	64.6	(9.8)	(4.0)	14.7	9.8

Quarterly (Rs mn)	Q3CY19	Q4CY19	Q1CY20	Q2CY20	Q3CY20
Revenue	35,276	40,603	35,017	26,008	35,373
EBITDA	5,563	5,406	5,859	5,244	6,707
EBITDA Margin (%)	15.8	13.3	16.7	20.2	19.0
PAT	3,000	2,692	3,199	2,680	3,631
EPS (Rs)	16.0	14.3	17.0	14.3	19.3

Source: Company, Emkay Research

Shareholding Pattern (%)	Sep-19	Dec-19	Mar-20	Jun-20	Sep-20
Promoters	54.5	54.5	54.5	54.5	54.5
FIIs	9.3	8.6	7.8	8.2	6.7
DIIs	21.1	21.1	20.9	18.3	25.5
Public and Others	15.1	15.7	16.7	19.0	13.3


Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
28-Sep-20	1,375	1,570	12m	Buy	Sanjeev Kumar Singh
21-Jul-20	1,379	1,570	12m	Buy	Sanjeev Kumar Singh
18-May-20	1,135	1,266	12m	Buy	Sanjeev Kumar Singh
26-Apr-20	1,157	1,266	12m	Buy	Sanjeev Kumar Singh
21-Apr-20	1,137	1,266	12m	Buy	Sanjeev Kumar Singh
01-Apr-20	963	1,287	12m	Buy	Sanjeev Kumar Singh
07-Feb-20	1,503	1,749	12m	Buy	Sanjeev Kumar Singh
20-Nov-19	1,484	1,767	12m	Buy	Sanjeev Kumar Singh
15-Oct-19	1,498	1,767	12m	Buy	Sanjeev Kumar Singh
23-Sep-19	1,676	1,855	12m	Buy	Sanjeev Kumar Singh
26-Aug-19	1,495	1,774	12m	Buy	Sanjeev Kumar Singh
18-Jul-19	1,567	1,774	12m	Hold	Sanjeev Kumar Singh
24-Jun-19	1,538	1,729	12m	Hold	Sanjeev Kumar Singh
13-Jun-19	1,583	1,729	12m	Hold	Sanjeev Kumar Singh
23-Apr-19	1,662	1,729	12m	Hold	Sanjeev Kumar Singh
28-Feb-19	1,422	1,691	12m	Buy	Sanjeev Kumar Singh
05-Feb-19	1,389	1,691	12m	Buy	Sanjeev Kumar Singh
07-Jan-19	1,478	1,836	12m	Buy	Sanjeev Kumar Singh
13-Dec-18	1,501	1,814	12m	Buy	Sanjeev Kumar Singh
17-Oct-18	1,540	1,814	12m	Buy	Sanjeev Kumar Singh
16-Oct-18	1,553	1,814	12m	Buy	Sanjeev Kumar Singh
03-Jul-18	1,333	1,613	12m	Buy	Sanjeev Kumar Singh
05-Apr-18	1,552	1,622	12m	Hold	Sanjeev Kumar Singh
09-Feb-18	1,661	1,805	12m	Hold	Sanjeev Kumar Singh
15-Dec-17	1,697	1,631	12m	Hold	Sanjeev Kumar Singh

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Alpha Portfolio – Cement & Building Materials



Analyst: Sanjeev Kumar Singh

Contact Details

sanjeev.singh@emkayglobal.com +91 22 6612 1255

Sector

Cement & Building materials

Analyst bio

Sanjeev Kumar Singh holds an MBA and has over 10 years of experience in the Cement sector. His team currently covers 17 stocks in the Cement and Building Materials space.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Cement & Building Materials	2.23	2.23	0%	0	100.00
ACC	0.20	0.22	10%	2	10.10
Ambuja Cements	0.28	0.32	14%	4	14.35
Grasim Industries	0.47	0.15	-69%	-33	6.53
Birla Corporation	0.00	0.07	NA	7	3.36
India Cements	0.00	0.00	NA	0	0.00
JK Cement	0.00	0.05	NA	5	2.25
Jk Lakshmi Cement	0.00	0.04	NA	4	1.94
Orient Cement	0.00	0.00	NA	0	0.00
Prism Johnson	0.00	0.00	NA	0	0.00
Ramco Cements	0.15	0.15	-1%	0	6.83
Shree Cements	0.32	0.31	-1%	0	14.10
Star Cement	0.00	0.00	NA	0	0.00
Ultratech Cement	0.80	0.90	13%	10	40.53
Century Plyboards	0.00	0.00	NA	0	0.00
Kajaria Ceramics	0.00	0.00	NA	0	0.00
Somany Ceramics	0.00	0.00	NA	0	0.00
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

EAP sector portfolio

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight


Sector portfolio NAV

	Base					Latest
	1-Apr-19	17-Jan-20	17-Apr-20	17-Jul-20	16-Sep-20	16-Oct-20
EAP - Cement & Building Materials	100.0	104.1	79.3	90.0	95.0	103.6
BSE200 Neutral Weighted Portfolio (ETF)	100.0	101.1	77.7	86.8	92.8	101.6

^{*}Performance measurement base date 1st April 2019

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

^{*} Not under coverage: Equal Weight

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 20 Oct 2020 00:52:16 (SGT) Dissemination Date: 20 Oct 2020 00:53:16 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayolobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 19, 2020
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research
 report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment
 recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of October 19, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 19, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 19, 2020

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

KESTRICTIONS ON L	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at
	persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com